Results 71 to 80 of about 23,927 (115)

ApoJ and apoL1 as novel determinants of MASH: a cross-sectional study. [PDF]

Lipids Health Dis
Cai Z, Najib S, Núñez-Sánchez MA, Martínez-Sánchez MA, García-Melgares C, Viguerie N, Rossell J, Julve J, Croyal M, Oliveira AR, Martínez CM, Dumas SJ, Genoux A, Frutos MD, Ramos-Molina B, Martinez LO.   +15 more
europepmc   +1 more source

The association between two common levels of apolipoprotein and chronic obstructive pulmonary disease: A Mendelian randomized study. [PDF]

Medicine (Baltimore)
Chen C, Sun Z, Zhong W, Zheng H, Zuo Z, Zhang X, Wang Y, Zhao W, Shen B.   +8 more
europepmc   +1 more source

SAA4: An Underdog Within the Serum Amyloid a Superfamily? [PDF]

Int J Mol Sci
Malle E, Madreiter-Sokolowski C, Windpassinger C.   +2 more
europepmc   +1 more source

Apolipoproteins in Chronic Kidney Disease and Kidney Transplant: A Long Unfinished Story. [PDF]

Int J Mol Sci
Secondulfo C, Izzo C, Vecchione N, Minelli G, Russo D, Russo D, Barra R, Molinaro G, Apicella L, Iacuzzo C, Pisani A, Hamzeh S, Amicone M, Cirillo M, Bilancio G.   +14 more
europepmc   +1 more source

Dysapolipoproteinaemia Influences the Relationship Between Very Low-Density Lipoprotein Cholesterol and Intra-Pancreatic Fat Deposition in Humans. [PDF]

Nutrients
Liu Y, Skudder-Hill L, Ko J, Shamaitijiang X, Sequeira-Bisson IR, Petrov MS.   +5 more
europepmc   +1 more source

Computational Selectivity Analysis of Aptamer toward Oxidized Low-Density Lipoprotein. [PDF]

ACS Omega
Chunta S, Khongwichit S, Prompat N, Nualla-Ong A, Amatatongchai M, Lieberzeit PA.   +5 more
europepmc   +1 more source

Engineering lipid nanoparticle surface hydrophobicity to modulate nano-bio interface and enable tissue-selective mRNA delivery. [PDF]

Biomaterials
Xu Z, Jolly KJ, Sankara CS, Mi K, Canchola A, Feng H, Gillen OP, Heiden KD, Basso KB, Chou WC, Lin Z, Zhang F.   +11 more
europepmc   +1 more source

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy. [PDF]

Arterioscler Thromb Vasc Biol
Reijnders E, Bossuyt PM, Jukema JW, Ruhaak LR, Romijn FPHTM, Szarek M, Trompet S, Bhatt DL, Bittner VA, Diaz R, Fazio S, Stevanovic I, Goodman SG, Harrington RA, White HD, Steg PG, Schwartz GG, Cobbaert CM.   +17 more
europepmc   +1 more source

Apolipoproteins and high-density lipoprotein phospholipids as indicators of atherosclerotic cardiovascular disease in Nigeria. [PDF]

Afr J Lab Med
Nwaejigh PC, Ebesunun MO, Udofia SS, Shakunle AA.   +3 more
europepmc   +1 more source

Plasma proteomic profiles of patients during oral anti-coagulant treatment with vitamin K antagonists. [PDF]

Br J Haematol
Camilleri E, van Vlijmen BJM, Bos MHA, Wuhrer M, Goodlett DR, Borchers CH, Cannegieter SC, van Rein N, Mohammed Y.   +8 more
europepmc   +1 more source